Ignite Creation Date:
2025-12-24 @ 2:17 PM
Ignite Modification Date:
2025-12-26 @ 12:53 PM
Study NCT ID:
NCT01089595
Status:
TERMINATED
Last Update Posted:
2017-03-15
First Post:
2010-01-28
Is NOT Gene Therapy:
True
Has Adverse Events:
True
Brief Title:
Trial of Tasigna (Nilotinib) 400 mg Twice Daily Alone or With Gleevec (Imatinib Mesylate) 400 mg Daily for Patients With Advanced Gastrointestinal Stromal Tumor (GIST)
Sponsor:
Fox Chase Cancer Center
Organization:
Key Dates - Follows AllAPIJSON File Order
Start Date:
2009-02
Start Date Type:
None
Primary Completion Date:
2011-11
Primary Completion Date Type:
ACTUAL
Completion Date:
2012-03
Completion Date Type:
ACTUAL
First Submit Date:
2010-01-28
First Submit QC Date:
None
Study First Post Date:
2010-03-18
Study First Post Date Type:
ESTIMATED
Results First Submit Date:
2013-05-07
Results First Submit QC Date:
None
Results First Post Date:
2017-03-15
Results First Post Date Type:
ACTUAL
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2017-01-25
Last Update Post Date:
2017-03-15
Last Update Post Date Type:
ACTUAL